GlassScriptPhysician profile
Shalu Singh
NPI 1245228998
$5,166.95
in general payments reported to CMS, 2019-2025
33 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $85.84 · 2021: $3,927 · 2022: $149 · 2023: $80.93 · 2024: $109 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,657.85 | 2021-2025 | Ubrelvy, Vraylar |
| Allergan, INC. | $323.31 | 2019-2021 | |
| Lundbeck LLC | $125.14 | 2019-2025 | Vyepti |
| Livanova USA, INC. | $108.18 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $87.07 | 2019-2023 | Briviact |
| Novartis Pharmaceuticals Corporation | $72.73 | 2019-2025 | |
| Genentech USA, INC. | $69.20 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Pfizer INC. | $59.47 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $57.28 | 2019-2024 | Austedo Xr |
| Eisai INC. | $53.95 | 2025 | |
| Amgen INC. | $52.68 | 2019-2023 | Aimovig |
| Lilly USA, LLC | $43.69 | 2019-2025 | Amyvid, Kisunla |
| Acadia Pharmaceuticals INC | $42.91 | 2019-2021 | |
| Neurelis, INC. | $34.07 | 2025 | Valtoco |
| Celgene Corporation | $32.41 | 2022-2025 | Zeposia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $30.23 | 2022-2025 | Ultomiris |
| Vanda Pharmaceuticals INC. | $30.04 | 2019-2025 | Ponvory |
| Avanir Pharmaceuticals, INC. | $27.53 | 2019 | |
| Supernus Pharmaceuticals, INC. | $26.63 | 2019 | |
| Genzyme Corporation | $25.61 | 2019 | |
| Emd Serono, INC. | $24.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.88 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.58 | 2022 | |
| Scilex Pharmaceuticals INC. | $17.15 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.26 | 2025 | Horizant |
| Axsome Therapeutics, INC. | $15.41 | 2025 | Symbravo |
| Sk Life Science, INC. | $15.08 | 2024 | |
| Tanabe Pharma America, INC. | $13.94 | 2024 | |
| Mdd US Operations, LLC | $13.84 | 2019 | |
| Biogen, INC. | $13.03 | 2019 | |
| Sumitomo Pharma America, INC. | $12.39 | 2023 | Aptiom |
| Adamas Pharmaceuticals, INC. | $11.40 | 2019 | |
| Kyowa Kirin, INC. | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shalu Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.